Engage with faculty in a closing live Q&A session to clarify your challenges in using CAR T-cell therapy in clinical practice. Don't miss this 60-minute whirlwind through CAR T-cell therapy best practices! Chair: Jesus G Berdeja, MDThe Greco-Hainsworth Tennessee Oncology Centers for ResearchNashville,  TN Speaker: Adriana Rossi, MD, MScMount SinaiNew York,  NY Emilie Desse, Answers in CMEEmail: [email protected] Registration for In-Person ProgramRegistration for Virtual ProgramAddressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia - What Clinicians Want to Know This program is supported by educational grants from AbbVie Inc, Astellas, and Daiichi Sankyo Inc. December 06, 20243:00 p.m. - 6:00 p.m. Pacific time Manchester Grand Hyatt San DiegoSeaport Ballroom ABCDThis 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with Acute Myeloid Leukemia (AML). Five clinical investigators will serve as faculty for the program, one of whom will moderate. To create a relevant agenda, prior to the symposium Research To Practice (RTP) will recruit 50 general medical oncologists/hematologists to complete a survey designed to evaluate their educational interests and knowledge deficiencies related to the treatment of AML. During the symposium, selected results from the survey highlighting areas of greatest interest will be presented. The faculty members will then review relevant research findings, discuss evidence-based treatment approaches and provide perspectives on ongoing studies. Actual questions contributed by the survey respondents as well as audience members will be integrated into the proceedings. The live activity will be recorded and developed into an enduring CME resource and promoted by RTP to 46,500 subscribers worldwide.Chair: Eytan M. Stein, MDMemorial Sloan-Kettering Cancer CenterNew York,  NY Speakers: Alexander E. Perl, MDUniversity of PennsylvaniaPhiladelphia,  PA Richard M. Stone, MDDana-Farber Cancer InstituteBoston,  MA Eunice S. Wang, MDRoswell Park Comprehensive Cancer CenterBuffalo,  NY Andrew H Wei, MBBS, PhD, FRACP, FRCPAPeter MacCallum Cancer CentreMelbourne,  VIC, Australia Sylvia Eriksen, Research To PracticeEmail: [email protected] Registration for In-Person ProgramRegistration for Virtual ProgramAddressing Current Questions and Controversies in the Management of Multiple Myeloma - What Clinicians Want to Know This program is supported by educational grants from GSK, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC and Karyopharm Therapeutics December 06, 20243:00 p.m. - 6:00 p.m. Pacific time Manchester Grand Hyatt San DiegoSeaport Ballroom EFGHThis 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with multiple myeloma (MM). Five clinical investigators will serve as faculty, one of whom will moderate. Prior to the symposium. Research To Practice (RTP) recruit 4 general medical oncologists/hematologists to consult on the project. The clinicians will participate in a live working group session during which they will voice challenging questions and cases from their practices and help shape the content for the symposium. The entire session will be recorded and video segments will be adapted for presentation during the event. The agenda for the live symposium will be divided into 5 modules. To begin each module, the moderator will play select video excerpts from the working group for the audience and the faculty. Moderated panel discussion will ensue to provide expert perspectives and answers to the questions introduced. A faculty member-led review of related research findings will complete each module. To make the event even more engaging, attendees will use iPads to submit their own questions and cases, which will be introduced and addressed periodically throughout the program. Virtual attendees will have the same capability via the webcast platform.Chair: Sagar Lonial, MDWinship Cancer Institute, Emory UniversityAtlanta,  GA Speakers: Philippe Moreau, MD, PhDUniversity Hospital Hôtel-DieuNantes,  France Robert Z. Orlowski, MD,PhDThe University of Texas MD Anderson Cancer CenterHouston,  TX Noopur RajeMassachusetts General HospitalBoston,  MA Paul G. RichardsonDana-Farber Cancer InstituteBoston,  MA Sylvia Eriksen, Research To PracticeEmail: [email protected] Registration for In-Person ProgramRegistration for Virtual ProgramBispecific Antibodies: A Playbook for Relapsed/Refractory Follicular Lymphoma This program is supported by Genmab and AbbVie December 06, 20243:00 p.m. - 6:00 p.m. Pacific time Marriott Marquis San Diego MarinaMarriott Grand Ballroom 11-13Access Program HereThis live panel discussion will focus on the advancing field of bispecific antibodies in third-line relapsed/refractory follicular lymphoma. Experts in the field of follicular lymphoma, with the added perspective of a patient advocate, will review best practices for assessing and applying the latest data on bispecific antibodies, as well as strategies to enhance shared decision-making and patient-centered care.Chair: Joshua Brody, MDIcahn School of Medicine at Mount SinaiNew York,  NY Speakers: Krish Patel, MDDirector, Lymphoma Research, Sarah Cannon Research InstituteNashville,  TN Lorna WarwickLymphoma CoalitionMississauga,  ON, CAN Vikki Chavis, MedscapeEmail: [email protected] Registration for In-Person ProgramRegistration for Virtual ProgramCases and Conversations™: The Rationale for Utilizing Non-Factor Replacement Therapies in Hemophilia Care This program is supported by Novo Nordisk, Inc. December 06, 20243:00 p.m. - 6:00 p.m. Pacific time San Diego Convention CenterRoom 6AHemophilia is an inherited bleeding disorder resulting from a deficiency in plasma coagulation proteins. The WFH recommends prophylactic treatment with replacement clotting factors starting before age 3 for all patients with a severe hemophilia. Prophylaxis has dramatically improved treatment, leading to reduced hospitalizations and absence from school or work and improving health related quality of life (HRQOL). Nevertheless, even with the progress achieved with replacement factors, therapy is costly and burdensome. New approaches to hemophilia treatment are therefore being developed to try and address these concerns. Through engaging case-based discussion and video animations, this accredited symposium will provide learners with insights regarding the pathophysiological pathways underlying hemophilia and new non-factor therapeutic strategies, the limitations in the current standard of care for hemophilia, and the role of non-factor replacement therapy in improving patient outcomes and quality of life.Chair: Steven R. Lentz, MD, PhDUniversity of IowaIowa City,  IA Speakers: Stacy E. Croteau, MD, MMSDirector Hemophilia/VWD program | Boston Children’s Hospital, Medical Director | Boston Bleeding Disorders Center, Assistant Professor of Pediatrics | Harvard Medical SchoolBoston,  MA Alice Ma, MDUniversity of North CarolinaChapel Hill,  NC Kelly McGregor, MJH EventsEmail: [email protected] Registration for Virtual ProgramRegistration for In-Person ProgramClinical assessment of gene therapies for hemophilia A and hemophilia B: Key takeaways for your practice This program is supported by CSL Behring December 06, 20243:00 p.m. - 6:00 p.m. Pacific time Marriott Marquis San Diego MarinaMarriott Grand Ballroom 8-9Access Program Here

This activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.

Cookie Settings | Support Opportunities | Privacy Policy | Terms of Service | Contact Us

This program is supported by Amgen Inc, Autolus Limited, Syndax Pharmaceuticals, Inc, and Takeda Pharmaceuticals U.S.A., Inc.

Commercial drones are primarily used for photography, videography, and other commercial applications. In contrast, law enforcement agencies use drones with advanced features like thermal cameras, real-time kinematics (RTK) sensors, and rapid deployment capabilities.

This CME/MOC/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, CLL Society.

Vaishali SanchorawalaBoston University Chobanian and Avedisian School of Medicine and Boston Medical CenterBoston,  MA

This program is supported by an independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME

Kangaroo definition: Any of various large herbivorous marsupials of the ... Do Not Sell My Personal Information. Copyright © 2024 LoveToKnow Media. All ...

Some of the most common drones for police departments outside the USA are the DJI Mavic, DJI Matrice 300 RTK, and DJI Mavic 2 Enterprise Advanced. Each drone has unique capabilities and payloads that have proven helpful for law enforcement.

This program is supported by Bristol Myers Squibb; Jazz Pharmaceuticals; Kura Oncology, Inc.; Rigel Pharmaceuticals, Inc.; and Syndax Pharmaceuticals, Inc.

Police dronesat night

Law enforcement agencies are also exploring new use cases for drones, such as drones for traffic management or monitoring critical infrastructure.

Some of the most common payloads include thermal imaging cameras, searchlights, and speakers to communicate with people on the ground.

Get great prices on our 12 pack of 7 inch Orange Traffic Safety Cones at Windy City Novelties. Free shipping available. Shop now!

This program is supported by Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Legend Biotech

Policeusingdrones forsurveillance

The options for treatment of diffuse large B-cell lymphoma (DLBCL) have expanded in recent years, particularly with the emergence of bispecific antibodies. Today's activity will focus on enhancing knowledge and competence in managing DLBCL at first relapse. The agenda includes discussions on treatment goals, factors influencing eligibility for different therapies, patient experiences, personalized treatment selection, and the emerging role of bispecific antibodies. You will learn about the patient perspective, communication strategies for shared decision-making, and considerations for integrating new therapies like bispecific antibodies. Interactive case-based discussions will highlight physician and patient perspectives in selecting therapy for patients who are not candidates for transplant or chimeric antigen receptor (CAR) T-cell therapy. The session will end with essential insights from the expert faculty, summarizing today's DLBCL management journey.Chair: Wendy Osborne, MDConsultant Haematologist, Honorary Clinical Senior Lecturer, Newcastle Hospitals – Newcastle UniversityNewcastle Upon Tyne,  United Kingdom Speakers: Natacha BolañosHead, Membership and Alliances, Lymphoma CoalitionMadrid,  Spain Gareth P. Gregory, MBBS(Hons), PhDAssociate Professor, Monash Health and Monash UniversityMelbourne,  Australia Gilles Salles, MD, PhDLymphoma Service Chief, Memorial Sloan Kettering Cancer CenterNew York,  NY Vikki Chavis, MedscapeEmail: [email protected] ACCESS PROGRAM HEREMaximizing Touchpoints to Empower Impactful Patient-Centered Care for Paroxysmal Nocturnal Hemoglobinuria This program is supported by Alexion and Novartis December 06, 202411:00 a.m. - 2:00 p.m. Pacific time Marriott Marquis San Diego MarinaMarriott Grand Ballroom 5-6Access Program Here

Body cameras are used by law enforcement to record public interactions and gather video evidence at crime scenes. Current body cameras are much lighter and ...

Law enforcement drone policy

This program is supported by independent educational grants from Bristol Myers Squibb, Geron, GSK, and CTI BioPharma Corp., a Sobi Company.

Wendy Osborne, MDConsultant Haematologist, Honorary Clinical Senior Lecturer, Newcastle Hospitals – Newcastle UniversityNewcastle Upon Tyne,  United Kingdom

Join our experts to elevate your MDS management and standards of care!Chair: Guillermo Garcia-Manero, MDThe University of Texas MD Anderson Cancer CenterHouston,  TX Speakers: Maria Diez-Campelo, MD, PhDUniversity Hospital of Salamanca, IBSALSalamanca,  Spain Valeria Santini, MDAOU Careggi, University of FlorenceFlorence,  Italy Lauren Wilkes, PVI, PeerView Institute for Medical EducationEmail: [email protected]

As a result, government agencies such as the Federal Aviation Administration have implemented strict regulations to ensure the cybersecurity of drone flight and drone operators.

This program is supported by Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Regeneron Pharmaceuticals, Inc.

To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.Chair: Rami S. Komrokji, MDH. Lee Moffitt Cancer Center and Research InstituteTampa,  FL Speakers: Gabriela S. Hobbs, MDMassachusetts General HospitalBoston,  MA Barbara Mora, MDDivision of Hematology, Ospedale ASST Sette LaghiVarese,  Italy Kelly McGregor, MJH EventsEmail: [email protected] Registration for Virtual ProgramRegistration for In-Person ProgramMedical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios This program is supported by Amgen Inc, Autolus Limited, Syndax Pharmaceuticals, Inc, and Takeda Pharmaceuticals U.S.A., Inc. December 06, 20243:00 p.m. - 6:00 p.m. Pacific time San Diego Convention CenterRoom 30Access Program Here

Canpoliceusedroneswithout a warrant

Find many great new & used options and get the best deals for Stun Gun Self-defense iPhone Case | Yellow Jacket Pink at the best online prices at eBay!

This program is supported by the International PNH Interest Group and educational grants from Alexion, Apellis, Sobi and Omeros

Christopher Patriquin, MD, MSc, FRCPCDivision of Medical Oncology and Hematology, University Health NetworkToronto,  ON, Canada

This program is supported by educational grants from CTI BioPharma, a Sobi Company, Geron Corporation, GSK, Incyte Corporation and Karyopharm Therapeutics

The drone policy about DJI equipment for law enforcement agencies in the USA is complex, with different regulations and restrictions depending on the state and agency. The U.S. Department of Commerce has placed DJI on its Entity List. Federal agencies, including the Department of Defense and the Department of the Interior, have imposed restrictions on using DJI drones due to cybersecurity concerns. In Florida, government agencies, including police, firefighters, and mosquito control districts, are forbidden from using drones manufactured by DJI. Every law enforcement agency in the USA will be reviewing their drone sourcing policy due to the Federal guidance.

Friday Satellite Symposia (FSS) are industry-supported, CME-accredited symposia that are offered the day preceding the American Society of Hematology (ASH) annual meeting. These sessions are not part of the official ASH annual meeting program and are planned solely by the organizing company.

Law enforcement agencies worldwide use drones to promptly and efficiently investigate highly dangerous and critical situations promptly and efficiently. These drones can cover a large area quickly, providing a better overview of the situation and allowing law enforcement to make more informed decisions.

An effective Drone program requires investments in police training, special equipment, and ongoing maintenance, and implementing a program may be prohibitive for some smaller police departments.

One of the primary concerns with using police drones is privacy and the impact on civil liberties. Aerial surveillance can be invasive, and many people are uncomfortable with being monitored from above. Law enforcement agencies must be careful to balance public safety with the privacy concerns of the community.

ASH appreciates its corporate and nonprofit partners for their participation in FSS. The Society values its partnerships and the supportive role that members of this community play in an effort to provide hematologists with quality educational programs. For more information, please review the 2024 FSS guidelines or contact Kelly Cade, Grants and Satellite Symposia Manager, Consultant, at [email protected].

Chula Vista Police Department, California, USA: The Chula Vista Police Department launched a Drone as a First Responder (DFR) program that uses autonomous drones with artificial intelligence technology to respond to emergencies. The DFR program utilizes autonomous drones with artificial intelligence to fly to an emergency before manned aircraft and gather critical information for responders. The program has reduced response time and aided the responder community in Chula Vista. Read more

Drones have proven to be highly effective in improving situational awareness and enhancing the capabilities of law enforcement operations. They are being used by police departments and other emergency response teams to provide immediate assistance when humans cannot efficiently reach them.

How far canpolice dronessee

200137 — Others such as AS 3780 (Class 8) also vary with. Packing Group and have different distances for closed and opened packages, for liquids and ...

USA law enforcement agencies are increasingly moving away from DJI solutions and embracing new providers such as Autel and Skydio. See our table below for more details.

The live portion of this activity will be presented as a 2.0-hour Friday Satellite Symposium (FSS). The activity is designed to highlight and test participants on the most clinically relevant data in NDMM, provide expert guidance on the interpretation of core concepts, and forecast the clinical impact of recent data sets. The activity will integrate a series of How We Do It® panel discussions alongside didactic presentations. To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session with faculty throughout the activity to emphasize areas of educational need, highlighting areas of debate, and illustrating the application of new data in defined clinical situations. To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.Chair: Ola LandgrenUniversity of MiamiMiami,  FL Speakers: Cristina Gasparetto, MDDuke University Medical CenterDurham,  NC Katja C. Weisel, MDDepartment of Oncology, Hematology and BMT, University Medical Center of Hamburg-EppendorfHamburg,  Germany Elijah Anseaume, Physicians' Education ResourceEmail: [email protected] Registration for Virtual ProgramRegistration for In-Person ProgramShow Me the Data™: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care? This program is supported by Incyte Corporation, Mallinckrodt Pharmaceuticals, and Sanofi December 06, 20247:00 p.m. - 10:00 p.m. Pacific time San Diego Convention CenterRoom 6AAccess Program Here

This program is supported by Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, both are Johnson and Johnson companies, and Sanofi.

This 90-minute patient-centric symposium will explore navigating the patient journey with asparaginase therapies as part of the treatment strategy for acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). The lively and engaging format will feature a series of video-based clinical vignettes, each modeling best practices in patient-clinician communication, contextualized within a review of the essential role of currently available asparaginase therapies in the optimal management of ALL/LBL. Faculty commentary and expert guidance will focus on how to select therapy, assess treatment efficacy, and recognize and manage the wide range of potential toxicities associated with asparaginase treatment. The expert faculty panel will include an adult hematologist/oncologist, a pediatric hematologist/oncologist, a hematologic oncology nurse specialist, and a patient advocate. Chair: Ibrahim Aldoss, MDCity of Hope Duarte Cancer CenterDuarte,  CA Speakers: Sandra Kurtin, PhD, ANP-BC, AOCN, FAPOClinical Assistant Professor of MedicineTucson,  AZ Luke Maese, DOUniversity of Utah, Huntsman Cancer Institute, Primary Children’s HospitalSalt Lake City,  UT Cate O'Reilly, MSWPatient and Caregiver Advocate, Cancer Support CommunityWashington,  DC Vikki Chavis, MedscapeEmail: [email protected] Registration for In-Person ProgramRegistration for Virtual ProgramUnleashing Emerging Therapies to Modify Myelofibrosis Pathogenesis: Shifting the Treatment Paradigm to Target Deeper Clinical and Molecular Responses This program is supported by PRIME Education, LLC December 06, 20243:00 p.m. - 6:00 p.m. Pacific time San Diego Convention CenterRoom 6DEJoin expert faculty as they take a deep dive into the latest clinical evidence and practical considerations for the personalized treatment of patients with myelofibrosis (MF) with JAK inhibitors and beyond. Informed by the diverse molecular targets and rationale for emerging MF therapies in late-stage clinical investigation, this satellite symposium will feature a review of the novel mechanisms of action and disease modifying potential of emerging MF therapies that will be reinforced through interactive polling questions and a 2D animation video, as well as expert insights on the potential positioning of these agents into MF treatment plans. Additionally, participants will have access to an up-to-date Myelofibrosis Clinical Trial Pocket Guide alongside the symposium to support the differentiation of the evolving landscape based on mechanisms of action, clinical trial design, and disease-modifying endpoints. Altogether, this satellite symposium is designed to prepare providers for the MF treatment paradigm shift, bringing combination therapy and disease modification to the forefront of patient-centered cares and durable outcomes.Chair: Jeanne Palmer, MDMayo Clinic - ArizonaScottsdale,  AZ Speakers: Douglas Burgoyne, PharmD, FAMCPUniversity of UtahSalt Lake City,  UT Marina Kremyanskaya, MD, PhDIcahn School of Medicine at Mount SinaiNew York,  NY Jeanne Palmer, MDMayo Clinic - ArizonaScottsdale,  AZ Pankit Vachhani, MDUniversity of Alabama at BirminghamBirmingham,  AL Lindsey Siegel, PRIME Education, LLCEmail: [email protected] Registration for In-Person ProgramRegistration for Virtual Program

Chan Y. Cheah, MBBS, FRACP, FRCPA, DMScSir Charles Gairdner Hospital and the University of Western AustraliaNedlands,  Australia

Britta Hoechsmann, MDInstitute for Clinical Transfusion Medicine and Immunogenetics, University of UlmUlm,  Germany

The rapid pace and sheer volume of basic science and therapeutic developments that continue to emerge in the field of ALL create practice and/or educational gaps, particularly for hematology-oncologists and oncology nurses who strive to deliver the best possible care to patients. This Medical Crossfire® will provide an ideal format for the leukemia care team to participate in an open exchange of ideas and viewpoints fostered by a case-based agenda allowing them to review patient scenarios, reflect on how they might handle particular cases, integrate relevant evidence into real-world practice, and compare their patient care approaches with those of experts and peers. Faculty leading discussion of common clinical scenarios and solutions will discuss methods to best integrate the latest therapies into ALL treatment paradigms, address barriers to optimized integration of these novel agents, as well provide best practices for the management of adverse events.Chair: Elias Jabbour, MDThe University of Texas MD Anderson Cancer CenterHouston,  TX Speakers: Hagop M. Kantarjian, MDThe University of Texas MD Anderson Cancer CenterHouston,  TX Aaron C. Logan, MD, PhDUniversity of California San FranciscoSan Francisco,  CA Rob Pieters, MD, PhDPrincess Máxima Center for Pediatric OncologyUtrecht,  Netherlands Claire Roddie, MD, PhDUniversity College London HospitalsLondon,  United Kingdom Ronald Viggiani, Physicians' Education ResourceEmail: [email protected] Registration for In-Person ProgramRegistration for Virtual ProgramSharing Best Practices from the ALL/LBL Clinic: Navigating Patient-Centered Care with Asparaginase Therapies This program is supported by Jazz Pharmaceuticals, Inc. December 06, 20243:00 p.m. - 6:00 p.m. Pacific time Marriott Marquis San Diego MarinaMarriott Grand Ballroom 5-6Access Program Here

Some of the most promising developments include using RTK (real-time kinematics) for improved mapping accuracy and integrating FLIR thermal cameras for real-time crime scene investigation.

Prof. John G. Gribben, MD, DScBarts Cancer Institute, Barts and The London School of Medicine, Queen Mary, University of LondonLondon,  United Kingdom

Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!

ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.

Drones, or unmanned aerial vehicles (UAVs), offer new ways for police departments to gather intelligence, respond to emergencies, and keep the public safe.

This program is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group and Regeneron Pharmaceuticals Inc.

As the demand for drone technology in law enforcement grows, companies like Autel and Skydio are working closely with police departments to develop new solutions that meet their unique needs.

In this activity, an interprofessional expert panel discusses the role of the interprofessional care team in the prophylaxis and management of acute graft-versus-host disease (aGVHD) according to current guidelines and available agents. The panel will also discuss emerging novel therapies for aGVHD prevention and treatment and hear from an experienced patient. Chair: Sung W. Choi, MD, MSUniversity of MichiganAnn Arbor,  MI Speakers: Paul CampbellPatient SpeakerAnn Arbor,  MI Chelsea Honstain, MS, FNP-CUniversity of Michigan HealthAnn Arbor,  MI Gianni ScappaticciUniversity of MichiganAnn Arbor,  MI Lisa Pagliaccetti, RMEI Medical Education, LLCEmail: [email protected] Addressing Current Questions and Controversies in the Management of Myelofibrosis - What Clinicians Want to Know This program is supported by educational grants from CTI BioPharma, a Sobi Company, Geron Corporation, GSK, Incyte Corporation and Karyopharm Therapeutics December 06, 202411:00 a.m. - 2:00 p.m. Pacific time Manchester Grand Hyatt San DiegoSeaport Ballroom EFGHThis 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with myelofibrosis. Four clinical investigators will serve as faculty for the program, one of whom will moderate. To create a relevant agenda, prior to the symposium Research To Practice (RTP) will recruit 50 general medical oncologists/hematologists to complete a survey designed to evaluate their educational interests and knowledge deficiencies related to the treatment of myelofibrosis. During the symposium, selected results from the survey highlighting areas of greatest interest will be presented. The faculty members will then review relevant research findings, discuss evidence-based treatment approaches and provide perspectives on ongoing studies. Actual questions contributed by the survey respondents as well as audience members will be integrated into the proceedings. The live activity will be recorded and developed into an enduring CME resource and promoted by RTP to 46,500 subscribers worldwide.Chair: Andrew T. Kuykendall, MDH. Lee Moffitt Cancer Center and Research InstituteTampa,  FL Speakers: Prithviraj Bose, MDThe University of Texas MD Anderson Cancer CenterHouston,  TX Angela G. Fleischman, MD, PhDUniversity of California, IrvineIrvine,  CA Abdulraheem Yacoub, MDUniversity of Kansas Cancer CenterLeawood,  KS Sylvia Eriksen, Research To PracticeEmail: [email protected] ACCESS PROGRAM HEREAddressing Current Questions and Controversies Regarding the Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Lymphoma - What Clinicians Want to Know This program is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group and Regeneron Pharmaceuticals Inc. December 06, 202411:00 a.m. - 2:00 p.m. Pacific time Manchester Grand Hyatt San DiegoSeaport Ballroom ABCDThis 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the utilization of CAR T-cell therapy and bispecific antibodies in the care of patients with non-Hodgkin lymphoma. Five clinical investigators will serve as faculty for the program, one of whom will moderate. Prior to the symposium. Research To Practice (RTP) recruit 4 general medical oncologists/hematologists to consult on the project. The clinicians will participate in a working group session during which they will voice challenging questions and cases from their practices and help shape the content for the symposium. The entire session will be recorded and video segments will be adapted for presentation during the event. The agenda for the symposium will be divided into 5 modules. To begin each module, the moderator will play select video excerpts from the working group for the audience and the faculty. Moderated panel discussion will ensue to provide expert perspectives and answers to the questions introduced. A faculty member-led review of related research findings will complete each module. To make the event even more engaging, attendees will use iPads to submit their own questions and cases. Virtual attendees will have the same capability via the webcast platform.Chair: Jeremy S. Abramson, MDMassachusetts General Hospital Cancer CenterBoston,  MA Speakers: Jennifer L. Crombie, MDDana-Farber Cancer InstituteBoston,  MA Martin Hutchings, MD, PhDCopenhagen University Hospital - RigshospitaletCopenhagen,  Denmark Matthew Lunning, DOUniversity of Nebraska Medical CenterOmaha,  NE Tycel J. J. Phillips, MDCity of HopeDuarte,  CA Sylvia Eriksen, Research To PracticeEmail: [email protected] ACCESS PROGRAM HEREAdvances in the Management of Myeloproliferative Neoplasms and Systemic Mastocytosis: Diagnosis/Classification, Risk Stratification, and Optimal Therapeutic Selection This program is supported by Blueprint Medicines Corporation; CTI BioPharma Corp., a Sobi Company; Incyte Corporation; and PharmaEssentia Corporation December 06, 202411:00 a.m. - 2:00 p.m. Pacific time Manchester Grand Hyatt San DiegoGrand Hall BThis symposium is CME-certified and will be presented live on Friday, December 6, 2024.

They can also be used for disaster response and search and rescue operations, allowing first responders to locate and assist those in need quickly.

Chaitra S. Ujjani, MDClinical Research Division, Fred Hutch Cancer Center; and Division of Oncology, University of WashingtonSeattle,  WA

The live portion of this symposium will be presented as a live 2-hour Friday Satellite Symposium (FSS) held prior to the ASH Annual Meeting. This live educational activity will feature key experts in the field of MPNs/SM who will use an interactive, case-based approach to explore personalized care across the treatment continuum. This activity is designed to provide clinicians with the latest trial data, real-world evidence, and clinical practice guidelines to ensure timely and accurate diagnosis of MPNs/SM, an understanding of SM variants and genetic mutations, and utilization of a patient-centered treatment approach to optimize therapeutic selection and manage treatment-related adverse events.

Drones can also be used to assist first responders in an emergency situation. For example, they can be deployed by drone operators to monitor wildfires, track the movement of dangerous animals, or assess the damage caused by natural disasters.

Although there are limitations and concerns around their use, their benefits in improved situational awareness, enhanced public safety, and faster response times make them valuable assets to any police department.

Ajay K. Nooka, MD, MPHDepartment of Hematology and Medical Oncology, Winship Cancer Institute, School of Medicine, Emory UniversityAtlanta,  GA

Drone technology is also helpful for search and rescue operations. Drones equipped with thermal cameras can quickly locate missing persons or victims of natural disasters, and first responders can use the images to identify the safest routes for rescue operations.

Using all our collective experience to help you navigate your choices of drone technology, solutions and services. We present you an unbiased view of what works for the most challenging environments – accurately, affordably, and safely.

Drones cannot replace a law enforcement officer, and their effectiveness depends on several factors, such as weather conditions and signal interference. Most importantly, drones should be used ethically and transparently in compliance with local law enforcement regulations.

Road construction is occurring. Prepare to slow. Watch for workers. Crews will be performing daytime single lane closures on US20 (Greenwood) between 4th and ...

In collaboration with, HealthTree Foundation for Myelofibrosis, PeerView’s Seminars & Workshop educational design will combine real-world cases with scientific evidence to demonstrate modern principles of treatment individualization with JAKi platforms, while also preparing the audience for the emergence of newer, innovative therapeutics targeting unique aspects of MF biology. Throughout, a panel of leading experts in myelofibrosis will illustrate:

To maximize the clinical outcomes for individual patients, practicing healthcare professionals must have mastered how to leverage the evidence and possess the competence to apply treatment guidelines and the latest emerging data with regard to the many recent approvals in this therapeutic space. To ensure competence and improve patient outcomes, strategic educational programming is necessary. This program will focus on how to best leverage emerging evidence for currently available therapies and proactively manage and mitigate treatment-related toxicities.Chair: Naval Daver, MDThe University of Texas MD Anderson Cancer CenterHouston,  TX Speakers: Jessica Altman, MDProfessor of Medicine, Hematology Oncology Division, Northwestern UniversityChicago,  IL Amir T. Fathi, MDMassachusetts General Hospital Cancer CenterBoston,  MA Gail J. Roboz, MDWeill Cornell Medicine/New York Presbyterian HospitalNew York,  NY Joshua F. Zeidner, MDUniversity of North CarolinaChapel Hill,  NC Kelly McGregor, MJH EventsEmail: [email protected] ACCESS PROGRAM HERENext Up: Conversations On Optimizing CD38 Antibody-Based Triplet Regimens For Early-Relapse Multiple Myeloma This program is supported by Sanofi December 06, 202411:00 a.m. - 2:00 p.m. Pacific time San Diego Convention CenterRoom 6BThey've become a game-changer in early relapse multiple myeloma: anti-CD38–based triplet regimens. These therapies have the potential to improve outcomes AND optimize quality of life. But do you know how to incorporate performance status, relapse aggressiveness, cytogenetics, and other patient-centered factors to tailor your treatment approach? Two myeloma experts will spend 60 minutes in a lively discussion and case-based debate on the latest updates in anti-CD38–based triplets for relapsed/refractory myeloma. They will also discuss best practices to promote diversity, equity, and inclusion in myeloma care. Then, a patient will join the experts to recount the highs and lows of their journey living with myeloma, and how their mindset prepared them for their fight against cancer.

This program is supported by AbbVie Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Sanofi

Gareth P. Gregory, MBBS(Hons), PhDAssociate Professor, Monash Health and Monash UniversityMelbourne,  Australia

Nicole Lamanna, MDHerbert Irving Comprehensive Cancer Center, New York-Presbyterian/Columbia University Medical CenterNew York,  NY

Mariana Castells, MD, PhDDepartment of Medicine, Division of Allergy and Clinical Immunology, Brigham and Women’s HospitalBoston,  MA

Law enforcementdrones forSale

This CME/MOC/AAPA activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for MDS.

Binod Dhakal, MBBSDivision of Hematology and Oncology, Department of Medicine, Medical College of WisconsinMilwaukee,  WI

This program is supported by Blueprint Medicines Corporation; CTI BioPharma Corp., a Sobi Company; Incyte Corporation; and PharmaEssentia Corporation

The live portion of this curriculum will be presented as a 2.5-hour Friday Satellite Symposium (FSS) held prior to the 2024 ASH Annual Meeting. This agenda has been developed in an interactive Show Me the Data format where experts will lead case-based panel discussions regarding the latest clinical advances in treating and managing patients with graft versus host disease (GvHD) with novel treatment approaches and emerging treatment strategies in the context of current paradigms. After each 'decision point' presentation, one faculty from the panel will convene to share their practice preferences and perspectives on the clinical trial data and clinical pearls from their practices. The chair will then challenge the faculty member to show them the data that backs up their decision making. Faculty will be probed on how emerging strategies under investigation may impact future treatment decision making. The program will also feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.Chair: Corey S. Cutler, MD, MPHDana-Farber Cancer InstituteBoston,  MA Speakers: Amin M. Alousi, MDThe University of Texas MD Anderson Cancer CenterHouston,  TX Yi-Bin Chen, MD, MSHarvard Medical SchoolBoston,  MA Carrie L. Kitko, MDVanderbilt University Medical CenterNashville,  TN Kelly McGregor, MJH EventsEmail: [email protected] Registration for In-Person ProgramRegistration for Virtual ProgramShow Me the Data™: Pushing CAR T’s Forward Across Lymphoid Malignancies... Accelerating Access in the Community and Treatment Strategies for the Road Ahead This program is supported by Autolus Limited and Novartis Pharmaceuticals Inc. December 06, 20247:00 p.m. - 10:00 p.m. Pacific time San Diego Convention CenterBallroom 20CDAccess Program Here

Expert faculty will focus on the important pillars related to the comprehensive and holistic care of patients with ITP, including disease-centered care, treatment-related considerations, and prioritizing patient-centered care. Faculty will expand on the mechanism of the disease and its causes, and the importance of a holistic approach. Presentations will revolve around the importance of defining clinical features and diagnostic criteria that are critical to diagnosis and treatment planning. A collaborative panel discussion will include insights into efficacy and safety data on current treatment options, choosing the best option for patients, and managing adverse events. In addition, the importance of patient perspectives and the caregiver’s roles will be discussed and how they can be integrated into collaborative decision-making. Speakers: Hanny Al-Samkari, MDMassachusetts General HospitalCambridge,  MA Rachael F. Grace, MD, MMScDana-Farber/Boston Children's Cancer and Blood Disorders CenterBoston,  MA Michael D Tarantino, MDBleeding and Clotting Disorders InstitutePeoria,  IL Vikki Chavis, MedscapeEmail: [email protected] ACCESS PROGRAM HERECrafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-based Platforms This program is supported by AstraZeneca, BeiGene, Janssen and Lilly December 06, 202411:00 a.m. - 2:00 p.m. Pacific time Marriott Marquis San Diego MarinaSan Diego Ballroom ABAccess Program Here

The live portion of this curriculum will be presented as a 3.0-hour Friday Satellite Symposium (FSS) held prior to the 2024 ASH Annual Meeting. This agenda has been developed in an interactive Show Me the Data format where experts will lead case-based panel discussions regarding the latest clinical advances in treating and managing patients with B-cell malignancies with novel T-cell therapy with novel treatment approaches and emerging treatment strategies in the context of current paradigms. After each 'decision point' presentation, one faculty from the panel will convene to share their practice preferences and perspectives on the clinical trial data and clinical pearls from their practices. The chair will then challenge the faculty member to show them the data that backs up their decision making. Faculty will be probed on how emerging strategies under investigation may impact future treatment decision making. The program will also feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.Chair: Alexey V. Danilov, MD, PhDCity of Hope National Medical CenterDuarte,  CA Speakers: Leidy L. Isenalumhe, MD, MSMoffitt Cancer CenterTampa,  FL Lori A. Leslie, MDJohn Theurer Cancer Center, Hackensack University Medical CenterHackensack,  NJ Mazyar Shadman, MD, MPHFred Hutchinson Cancer CenterSeattle,  WA Jason R. Westin, MDThe University of Texas MD Anderson Cancer CenterHouston,  TX Elijah Anseaume, Physicians' Education ResourceEmail: [email protected] Registration for In-Person ProgramRegistration for Virtual Program

The payload capacity of drones used by law enforcement agencies varies depending on the drone type. DJI Matrice 300 RTK, for example, has a maximum payload capacity of up to 2.7 kilograms, making it ideal for carrying specialized payloads like FLIR cameras and other mission-critical equipment.

Law enforcement agencies and police departments often use commercial drones such as DJI Mavic and Autel Robotics in cities like Las Vegas and Chula Vista.

Stacy E. Croteau, MD, MMSDirector Hemophilia/VWD program | Boston Children’s Hospital, Medical Director | Boston Bleeding Disorders Center, Assistant Professor of Pediatrics | Harvard Medical SchoolBoston,  MA

In some jurisdictions, U-turns are only allowed at intersections, while in others, they may be permitted mid-block. Look for Signage: Ensure there are no signs ...

This program is supported by educational grants from GSK, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC and Karyopharm Therapeutics

This 90-minute symposium will feature 3 multidisciplinary expert faculty. The symposium is designed to engage attendees in an interactive experience focused on key challenges and therapeutic advances in the management of AL amyloidosis. The overall goal of this symposium is for learners to be better able to integrate evidence-based strategies for the optimal care of patients with AL amyloidosis. Chair: Morie A. Gertz, MDMayo ClinicRochester,  MN Speakers: Suzanne Lentzsch, MD, PhDColumbia University Herbert Irving Comprehensive Cancer CenterNew York,  NY Vaishali SanchorawalaBoston University Chobanian and Avedisian School of Medicine and Boston Medical CenterBoston,  MA Vikki Chavis, MedscapeEmail: [email protected] ACCESS PROGRAM HEREEvolving Treatment Paradigms for Patients with Hemoglobinopathies This program is supported by Vertex Pharmaceuticals December 06, 202411:00 a.m. - 2:00 p.m. Pacific time San Diego Convention CenterRoom 30The most common monogenic global disorders worldwide are hemoglobinopathies, genetic diseases related to hemoglobin (Hb) synthesis. The genetic cause of hemoglobinopathies are DNA variants in or near the globin genes. It has been estimated that 7% of the global population carry a DNA variant, with the majority of diagnosed individuals having sickle cell disease, and the minority are affected by ß-thalassemia. Though diverse, the burden of hemoglobinopathies is known to be severe and disabling for many individuals, requiring specialized multidisciplinary management. This accredited symposium will feature engaging, case-based discussions among 4 experts highlighting clinical trial data for gene therapies and strategies for integrating gene therapy into the individualized management of hemoglobinopathies, including sickle cell disease and transfusion-dependent thalassemia.Chair: Biree Andemariam, MDUniversity of Connecticut HealthWest Hartford,  CT Speakers: Farzana Sayani, MD, MScUniversity of PennsylvaniaPhiladelphia,  PA Sujit Sheth, MDWeill Cornell MedicineNew York,  NY Kelly McGregor, MJH EventsEmail: [email protected] ACCESS PROGRAM HEREFrom Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice This program is supported by Sanofi and Takeda Pharmaceuticals USA, Inc. December 06, 202411:00 a.m. - 2:00 p.m. Pacific time San Diego Convention CenterRoom 6AAccess Program Here

Stacy E. Croteau, MD, MMSDirector Hemophilia/VWD program | Boston Children’s Hospital, Medical Director | Boston Bleeding Disorders Center, Assistant Professor of Pediatrics | Harvard Medical SchoolBoston,  MA

Join our closing live Q&A to challenge our experts and enhance your understanding of these therapies. Connect with experts, stay informed, and be part of the RRMM care revolution!Chair: Thomas G. Martin, MDProfessor University of California, San Francisco, Associate Chief, Hematology/OncologySan Francisco,  CA Speakers: Kenneth Capps, JDPatient AdvocateAsheville,  NC Carlyn Rose Tan, MDMemorial Sloan Kettering Cancer CenterNew York,  NY Emilie Desse, Answers in CMEEmail: [email protected] ACCESS PROGRAM HERETreatment Crossroads: Diverse Perspectives on Treatment Strategies for Relapsed/Refractory DLBCL and FL This program is supported by PRIME Education, LLC December 06, 202411:00 a.m. - 2:00 p.m. Pacific time San Diego Convention CenterRoom 6DEJoin expert faculty as they take a deep dive into the latest clinical evidence and practical considerations for treatment of complex cases of patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Informed by real-world data on top challenges regarding the selection, sequencing and integration of novel therapies in DLBCL management plans, this satellite symposium will support lymphoma care teams in examining the latest evidence, differentiating new and emerging novel CAR T-cell and bispecific antibody therapies for DLBCL and FL, and addressing barriers to novel therapy adoption. The topics for discussion by the expert faculty panel will be supported by clinical cases and enhanced by interactive polling questions and live questions submitted by attendees throughout the presentation. Altogether, this satellite symposium will harness real-world experiences providing DLBCL and FL care to deepen the impact of the education, utilizing a case-based approach to provide a basis for discussion and strategy of the optimal integration of novel therapies to enhance patient-centered care and improve outcomes.Chair: Paolo Strati, MDThe University of Texas MD Anderson Cancer CenterHouston,  TX Speakers: Douglas Burgoyne, PharmD, FAMCPUniversity of UtahSalt Lake City,  UT Nathan Fowler, MDThe University of Texas MD Anderson Cancer CenterHouston,  TX Manali Kamdar, MD, MBBSUniversity of Colorado Cancer CenterAurora,  CO Paolo Strati, MDThe University of Texas MD Anderson Cancer CenterHouston,  TX Eryn Litvinas, PRIME Education, LLCEmail: [email protected] ACCESS PROGRAM HERE

This program is supported by AstraZeneca, Genmab US, Inc. and Ipsen Biopharmaceuticals, Inc. Provided by Clinical Care Options, LLC in partnership with the Follicular Lymphoma Foundation.

The DJI Matrice 300 RTK is another option, offering improved flight stability and RTK capabilities for accurate mapping and surveying.

This program is supported by educational grants from AstraZeneca, BeiGene, and Lilly. Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options.

In collaboration with our partner the HealthTree Foundation for MDS, PeerView’s unique Seminars & Tumor Board live event will pair compelling case scenarios and collaborative decision-making (designed to mimic the back-and-forth of real-world tumor boards) with practice-changing evidence to provide guidance on the skills and strategic planning that inform treatment individualization across the spectrum of MDS management—while addressing real-world barriers that can prevent accurate patient assessment and hinder the delivery of modern therapeutic standards. Throughout the activity, a panel of leading MDS experts will collaboratively illustrate:

We are a specialist manufacturer and supplier of, you guessed it, bunting! Based in Shepshed, The Midlands, we supply the whole of the UK.

Don’t miss this opportunity to upgrade your skills in customizing CLL care!Chair: Prof. John G. Gribben, MD, DScBarts Cancer Institute, Barts and The London School of Medicine, Queen Mary, University of LondonLondon,  United Kingdom Speakers: Matthew S. Davids, MD, MMScDana-Farber Cancer Institute, Harvard Medical SchoolBoston,  MA Nicole Lamanna, MDHerbert Irving Comprehensive Cancer Center, New York-Presbyterian/Columbia University Medical CenterNew York,  NY Meghan C. Thompson, MDMemorial Sloan Kettering Cancer CenterNew York,  NY Lauren Wilkes, PVI, PeerView Institute for Medical EducationEmail: [email protected] ACCESS PROGRAM HEREEmerging insights in biology and treatment approaches to Peripheral T cell Lymphomas This program is supported by Acrotech Biopharma December 06, 202411:00 a.m. - 2:00 p.m. Pacific time Marriott Marquis San Diego MarinaPacific Ballroom Salons 18-19Peripheral T-cell lymphoma (PTCL) represents a group of heterogeneous and aggressive non-Hodgkin lymphomas with generally poor prognosis. Despite advances in understanding the underlying biology, treatment outcomes have remained suboptimal. This symposium, supported by Acrotech, and provided by the University of Texas MD Anderson Cancer Center with MD Education, will explore groundbreaking therapies and the shifting paradigm in PTCL treatment. Renowned experts will dissect the complexity of PTCL biology, discuss innovative therapeutic strategies, and address the challenges faced in clinical practice. Presentations will include insights into nodal T-cell lymphoma epigenetics, CAR-T cell therapy applications, and novel approaches for rare PTCL subtypes. This educational event promises to answer pivotal questions in PTCL management, focusing on improving patient outcomes and quality of life. With a blend of didactic sessions, interactive panels, and case studies, attendees will be at the forefront of translating emerging research into transformative patient care.Chair: Swami P. Iyer, MDThe University of Texas MD Anderson Cancer CenterHouston,  TX Speakers: Kate Cwynarski, MBBS, PhD, FRCP, FRCPathUniversity College London HospitalLondon,  United Kingdom Luis Malpica, MDThe University of Texas MD Anderson Cancer CenterHouston,  TX Yun Kyoung Tiger, MD, PhDRutgers Robert Wood Johnson Medical SchoolNew Brunswick,  NJ Jasmine Zain, MDCity of HopeDuarte,  CA Christopher Bolwell, MD EducationEmail: [email protected] Escape the Amyloid Maze: Unraveling Data and Care Strategies for AL Amyloidosis This program is supported by Prothena, Janssen and Alexion December 06, 202411:00 a.m. - 2:00 p.m. Pacific time Marriott Marquis San Diego MarinaMarriott Grand Ballroom 8-9Access Program Here

Austin G. Kulasekararaj, MD, MBBS, FRCPath, MRCPKing's College Hospital NHS Foundation TrustLondon,  United Kingdom

Policedrone cost

Join us live and in person for an exciting discussion on assessing gene therapies for hemophilia A and hemophilia B. Hematologists, emergency medicine physicians, nurses, nurse practitioners, physician assistants, and other members of the hemophilia care team will benefit from this interactive and nuanced discussion by an expert panel on the clinical and practical evidence surrounding gene therapies for hemophilia, the differences in gene therapies for hemophilia A and hemophilia B, how to identify eligible candidates for gene therapies for hemophilia A and B, monitor patients with hemophilia who receive gene therapies, and how to counsel patients and colleagues about gene therapies for hemophilia A and B.Speakers: Amy Dunn, MDNationwide Children's HospitalColumbus,  OH Steven W. Pipe, MDUniversity of MichiganAnn Arbor,  MI Doris V. Quon, MD, PhDOrthopaedic HospitalLos Angeles,  CA Vikki Chavis, MedscapeEmail: [email protected] Registration for In-Person ProgramRegistration for Virtual ProgramCollaboration In Chronic ITP: Improving Quality Of Life And Patient Outcomes This program is supported by an independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME December 06, 20243:00 p.m. - 6:00 p.m. Pacific time San Diego Convention CenterBallroom 20ABThe management of patients with immune thrombocytopenia (ITP) remains challenging, requiring individualized strategies that incorporate patient preferences with the aim of relieving symptoms and improving wellbeing. Hear a patient's view on the impact of living with ITP and its effect on quality of life, before the expert faculty provide practical insights on current and emerging treatments for chronic ITP and how these may be utilized to improve outcomes for patients, including case-based presentations to review management strategies for different patient profiles. Finally, a panel discussion with all three faculty will focus on shared decision-making and collaboration in the clinic, to give patients with chronic ITP the best possible outcomes. The symposium will include interactivity throughout via audience polling and Q&A sessions.Chair: Cindy E Neunert, MDColumbia University Irving Medical CenterNew York,  NY Speakers: David J Kuter, MD, DPhilMassachusetts General HospitalBoston,  MA María Eva Mingot-Castellano, MDHospital Universitario Virgen del RocíoSevilla,  Spain Lucienne Pratt, touchIMEEmail: [email protected] Registration for In-Person ProgramComplex Cases in the Community Clinic: Managing Diverse Hematologic Malignancies This program is supported by Sanofi and Incyte Corporation December 06, 20243:00 p.m. - 6:00 p.m. Pacific time Marriott Marquis San Diego MarinaMarriott Grand Ballroom 2-4This 120-minute symposium will emulate a typical day for a community hematologist/oncologist, highlighting the diversity of hematologic malignancies and the complex decisions faced daily through a series of patient cases. A panel of expert hematologist/oncologists will evaluate and discuss challenging patient scenarios using recent clinical data, treatment guidelines, and best practices to optimize access to care. The symposium will emphasize patient-centric care and shared decision-making as top priorities, addressing the practical challenges that busy community clinicians encounter. Through this focus on real-world cases and evidence-based strategies, the event aims to enhance the integration of innovative treatments and improve patient outcomes in the community setting. Chair: Matthew Matasar, MD, MSDivision of Blood Disorders, Rutgers Cancer Institute of New Jersey and RWJBarnabas HealthNew York,  NY Speakers: Chan Y. Cheah, MBBS, FRACP, FRCPA, DMScSir Charles Gairdner Hospital and the University of Western AustraliaNedlands,  Australia Luciano J. Costa, MD,PhDUniversity of Alabama at BirminghamVestavia,  AL Nisha S. Joseph, MDWinship Cancer Institute of Emory UniversityAtlanta,  GA Chaitra S. Ujjani, MDClinical Research Division, Fred Hutch Cancer Center; and Division of Oncology, University of WashingtonSeattle,  WA Vikki Chavis, MedscapeEmail: [email protected] Registration for In-Person ProgramRegistration for Virtual ProgramMedical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET This program is supported by MorphoSys and Protagonist Therapeutics Inc. December 06, 20243:00 p.m. - 6:00 p.m. Pacific time San Diego Convention CenterBallroom 20CDMedical Crossfire® is one of PER’s signature educational formats and is a nationally-recognized medical education modality dedicated to improving medical practices and patient care through debate, discussion, and authoritative peer exchange on critical clinical issues. The design of the Medical Crossfire® is based on the understanding that exposure to differing – and sometimes provocative – opinions, insights, and philosophies fuels improved learning and knowledge among healthcare professionals. This Medical Crossfire® formatted satellite program will include a chair and panel of four faculty experts in MPNs, featuring a series of brief didactic presentations, followed by discussion between faculty on key questions and common cases in the field.

DISCLOSURE: Viper Drones is supported by its audience. When you purchase through links on our site, at no cost to you, we may earn an affiliatecommission.

Matthew Matasar, MD, MSDivision of Blood Disorders, Rutgers Cancer Institute of New Jersey and RWJBarnabas HealthNew York,  NY

Throughout this educational session, discussion spurred by patient cases, continuous clinical practice polling questions, and a live Q&A session will enhance learner engagement.Chair: John O. Mascarenhas, MDTisch Cancer Institute, Icahn School of Medicine at Mount SinaiNew York,  NY Speakers: Mariana Castells, MD, PhDDepartment of Medicine, Division of Allergy and Clinical Immunology, Brigham and Women’s HospitalBoston,  MA Daniel J. DeAngelo, MDDana-Farber Cancer InstituteBoston,  MA Raajit Rampal, MD, PhDMemorial Sloan Kettering Cancer CenterNew York,  NY Kristin Ciszeski, HMP GlobalEmail: [email protected] Application of Evolving Evidence in Mantle Cell Lymphoma: Therapeutic Strategies Using BTK Inhibitors This program is supported by AstraZeneca. Provided by Clinical Care Options, LLC December 06, 202411:00 a.m. - 2:00 p.m. Pacific time Manchester Grand Hyatt San DiegoGrand Hall DThe care of patients with mantle cell lymphoma (MCL) is becoming increasingly complex with new indications for BTK inhibitors and emerging data transforming management strategies. CCO proudly presents this live interactive symposium, designed to equip clinicians with the knowledge and insights needed to confidently navigate the rapidly evolving landscape of MCL patient care. Engage directly with leading experts through Q&A sessions, patient case discussions, and review of a 2025 MCL treatment algorithm. These interaction with the panelests will enhance your understanding and application of cutting-edge treatments for both newly-diagnosed and R/R disease. Join us for a dynamic and informative experience that will empower you to implement the latest treatment advances in BTK inhibitors for MCL and improve patient outcomes.Chair: Julie M. Vose, MD, MBAUniversity of Nebraska Medical CenterOmaha,  NE Speakers: Brad S. Kahl, MDWashington University School of Medicine in St. LouisSt. Louis,  MO John P. Leonard, MDWeill Cornell MedicineNew York,  NY Ishana Fleurant, Clinical Care OptionsEmail: [email protected] ACCESS PROGRAM HERECollaborating for Optimal Immune Thrombocytopenia Care: Uniting Disease, Treatment, and Patient-Centered Considerations This program is supported by SOBI, Novartis, and Rigel Pharmaceuticals, Inc. December 06, 202411:00 a.m. - 2:00 p.m. Pacific time Marriott Marquis San Diego MarinaMarriott Grand Ballroom 11-13Access Program Here

Drones provide a bird’s eye view of any situation, providing police and law enforcement agencies with a complete situational overview. This perspective enables them to understand the situation better and take quick action to manage it.

How big arepolice drones

In addition to the standard Federal Aviation Administration regulations regarding drone use, many jurisdictions require permits or special training for law enforcement officers to operate drones, and there are strict guidelines for how and when they can be used.

Alexander Röth, MDDepartment of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-EssenEssen,  Germany

This interactive, live symposium will focus on all aspects of PNH through the lens of the patient journey. Expert faculty will review the complement pathway, highlight diagnostic challenges, and discuss current and emerging treatment options, while listening to a patient share their experiences. A collaborative approach to patient care will be a key focus of the presentation as faculty prioritize care and quality of life for patients with PNH.Speakers: Srikanth NagallaBaptist Health South FloridaMiami,  FL Christopher Patriquin, MD, MSc, FRCPCDivision of Medical Oncology and Hematology, University Health NetworkToronto,  ON, Canada Vikki Chavis, MedscapeEmail: [email protected] ACCESS PROGRAM HEREMedical Crossfire®: Bridging Evidence to Practice in AML... Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials This program is supported by Bristol Myers Squibb; Jazz Pharmaceuticals; Kura Oncology, Inc.; Rigel Pharmaceuticals, Inc.; and Syndax Pharmaceuticals, Inc. December 06, 202411:00 a.m. - 2:00 p.m. Pacific time San Diego Convention CenterBallroom 20CDAccess Program Here

TD app; EasyWeb · WebBroker · U.S. Banking. EasyWeb Login. Username or Access Card. Description (Optional). Password. Remember me. Login. Forgot your username ...

Drones enable law enforcement agencies to conduct operations from a safe distance. They can gather intelligence information, monitor crowds, manage traffic, and aid in search and rescue operations.

Thomas G. Martin, MDProfessor University of California, San Francisco, Associate Chief, Hematology/OncologySan Francisco,  CA

The 2024 FSS will be held on Friday, December 6. Each symposium will be presented once according to the program schedule and offers free registration. To register, click the “Registration” button below each title in the FSS program schedule. Check back as registration links will continue to be added as managing companies share them with ASH. For program-specific questions, please reach out to the managing company contact listed below each FSS session.

A drone program can provide local law enforcement agencies an enhanced ability to manage emergencies quickly and efficiently. It reduces the response time, increases situational awareness, and improves officer safety—all while reducing operating costs.

Katja C. Weisel, MDDepartment of Oncology, Hematology and BMT, University Medical Center of Hamburg-EppendorfHamburg,  Germany

This program is supported by an independent educational grant from CSL Behring LLC. Provided by RMEI Medical Education, LLC.

This activity will equip learners with the skills to master the modern science of MF care, and offer enhanced outcomes to patients.Chair: Professor Claire HarrisonGuy's and St Thomas' NHS Foundation TrustLondon,  ENG, United Kingdom Speakers: Catriona Jamieson, MD, PhDSanford Stem Cell Institute, CIRM UC San Diego Alpha Stem Cell ClinicLa Jolla,  CA Professor Francesco Passamonti, MDUniversity of MilanoMilano,  Italy Lauren Wilkes, PVI, PeerView Institute for Medical EducationEmail: [email protected] MDS 2024: Let’s Overcome the Challenges This program is supported by MDS Foundation, Inc. December 06, 20247:00 a.m. - 10:00 a.m. Pacific time Manchester Grand Hyatt San DiegoGrand Hall BThe MDSF ASH 2024 Symposium will focus on challenges the MDS community faces in 2024. Progress has been made in understanding the biology, genetics and pathogenesis of MDS. Prognostication, and treatment strategies have been improved, but not satisfactorily. In 2024 we are still facing problems: Can we assess minimal residual disease ? We are still debating regarding the recommended Hb threshold for RBC transfusions. The increasing role of inflammation in the disease pathogenesis, raises the question of anti-inflammatory treatment. The reports on germline mutations and their role in MDS in adulthood might change our genetic screening policy. Finally, we are still puzzled whether patients with higher-risk disease should be treated with hypomethylating agents only, as the only proven treatment, or additional therapy might improve the outcome. The symposium will highlight these challenges, and based on recent advances in the field, potential solutions will be presented and discussed.Chairs: Moshe Mittelman, MDTel Aviv Sourasky Medical CenterTel Aviv,  Israel Casey L. O'Connell, MDUSC Keck School of Medicine, University of Southern CaliforniaLos Angeles,  CA Speakers: Lionel Ades, MD,PhDUniversité Paris Cité, APHP, Hôpital Saint-LouisParis,  France Rena Buckstein, MD, FRCPCSunnybrook Health Sciences Centre, University of TorontoToronto,  ON, Canada Aristoteles Giagounidis, MDMarienhospital DüsseldorfDüsseldorf,  Germany Jaroslaw MaciejewskiTaussig Cancer Institute, Cleveland Clinic FoundationCleveland,  OH Ghulam MuftiKing's College HospitalLondon,  United Kingdom Esther Natalie Oliva, MDGrande Ospedale Metropolitano Bianchi Melacrino MorelliReggio Calabria,  Italy Magnus Tobiasson, MDKarolinska InstitutetStockholm,  Sweden Lachelle D. Weeks, MD, PhDDana-Farber Cancer InstituteBoston,  MA Lea Harrison, MDS Foundation, Inc.Email: [email protected] Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease This program is supported by independent educational grants from AbbVie, Bristol Myers Squibb, and Geron. December 06, 20247:00 a.m. - 10:00 a.m. Pacific time Marriott Marquis San Diego MarinaSan Diego Ballroom ABAccess Program Here

Law enforcement drones are unmanned aerial vehicles (UAVs) used by police departments to observe and monitor areas from the air. They are equipped with cameras, sensors, and other payloads to gather intelligence, detect threats, and respond to emergencies.

Drone use for public safety applications has been discussed for many years, and law enforcement agencies are starting to take notice.

The large model with a volume of 120 l or a model for dog waste with integrated space for special bags completes this trendy range of litter bins. Galvanised ...

Additionally, payloads such as cameras and communication systems are vulnerable to hacking, posing grave danger to police officers during tactical operations and crime scenes.

Drones can quickly and easily provide a bird’s eye view of a situation, allowing law enforcement officers to assess the scene from a safe distance.

Bring your questions—the myeloma experts will do their best to address them, giving you more tools to improve your myeloma practice, and your patients' lives.Chair: Caitlin Costello, MDUniversity of California, San DiegoSan Diego,  CA Speaker: Rahul Banerjee, MD, FACPUniversity of WashingtonSeattle,  WA Veronica Bohorquez-Medd, Multiple Myeloma Research FoundationEmail: [email protected] Championing the Care of Relapsed/Refractory Multiple Myeloma: Practical Strategies to Integrate Bispecific Antibodies This program is supported by Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Regeneron Pharmaceuticals, Inc. December 06, 20247:00 a.m. - 10:00 a.m. Pacific time San Diego Convention CenterRoom 6AIt's great to have options, and we have more options than ever before for managing heavily pretreated, relapsed/refractory multiple myeloma. The emergence of the new antibodies on the block—bispecifics—has led to notable improvements in outcomes for patients with advanced disease. But more options also means more decisions to be made about patient selection and sequencing. In this 60-minute session, two myeloma experts will discuss all of the practical considerations for integrating bispecific antibodies into the treatment of patients with heavily pretreated, relapsed myeloma. The faculty will both review the clinical evidence and guide you on what it means for your practice. Topics to be addressed include: how bispecific antibodies compare with CAR T-cell therapies, and when each should be used; recommended patient-centered strategies for preventing and managing treatment-related side effects; and how to facilitate collaborative care across clinics and providers to improve our patients' clinical outcomes and lives overall. Come prepared for a lively session and Q&A on this important clinical topic.Chair: Ajai Chari, MDUniversity of California, San FranciscoSan Francisco,  CA Speaker: Amrita Y Krishnan, MD, FACPCity of Hope Comprehensive Cancer CenterDuarte,  CA Veronica Bohorquez-Medd, Multiple Myeloma Research FoundationEmail: [email protected] Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience + Innovation for More Personalized Disease Control This program is supported by independent educational grants from Bristol Myers Squibb, Geron, GSK, and CTI BioPharma Corp., a Sobi Company. December 06, 20247:00 a.m. - 10:00 a.m. Pacific time Marriott Marquis San Diego MarinaPacific Ballroom Salons 18-19This CME/MOC/AAPA activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Myelofibrosis.

In collaboration with CLL Society, PeerView’s unique Clinical Consults event will provide useful information and practical instruction in an engaging, interactive manner designed to explore the rapid transformation of modern CLL therapy. Expert conversations on treatment choices will be paired with practically-oriented case discussions to provide learners with guidance on addressing common clinical challenges arising from the upfront and sequential management of CLL to strategies for integrating emerging, innovative modalities into care. Throughout, the experts will cover:

Drones can be used to zoom in on dangerous situations that are too risky for law enforcement officers to approach. For example, they can monitor active shooter situations or hostage crises from a safe distance.

To prevent cyber threats and ensure public safety, law enforcement agencies must train their officers in the safe and responsible use of surveillance drones while taking the necessary precautions to secure drone footage and protect civil liberties.